

#22 goiga

Attorney's Docket No. 029395-017

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APRIL

In re Patent Application of) APR 1 5 2003		
Joyce TAYLOR-PAPADIMITRIOU et al.	Group Art Unit: 1644 TECH CENTER 1600/2900		
Application No.: 09/658,621	Examiner: Amy M. Decloux		
Filed: September 8, 2000	Confirmation No.: 3359		
For: MUC-1 DERIVED PEPTIDES	, ,		

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

A check in the amount of \$ is enclosed for the fee due.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: April 11, 2003

1

Christopher L. North, Ph.D. Registration No. 50,433

Patent Attorney's Docket No. 029395-017



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED

				" U
In re Pa	atent Application of)		APR 1 5 2003
Joyce T	TAYLOR-PAPADIMITRIOU et al.)	Group Art Unit: 1644	TECH CENTER 1600/2900
Applica	ation No.: 09/658,621)	Examiner: Amy M. Decla	oux
Filed:	September 8, 2000)	Confirmation No.: 3359	
For:	MUC-1 DERIVED PEPTIDES)		

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since the documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b) no fee or statement is required.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: April 11, 2003

Christopher L. North, Ph.D. Registration No. 50,433

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

SHEET 1 OF 1

Súbstitute for forms 1449A/PTO & 1449B/PTO

TOWN THE

Examiner

ATTORNEY'S DKT NO. 029395-017 09/594624

APPLICATION NO. 09/594624

APPLICA

INFORMATION DISCLOS

U.S. PATENT DOCUMENTS

			U.S. PATENT DOCUMENTS						
Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applica of Cited Document	ant	Issue/Publication Date (MM-DD-YYYY)				
		FO	REIGN PATENT DOCUMENTS						
Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication Translation (MM-DD-YYYY) Yes No					
	00/06723 •		WO	(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	- 103 100				
	98/50527		WO		_				
	0 369 816 '		EP	-					
,		NON PA	ATENT LITERATURE DOCUMENTS						
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.								
A-1	Pei-Xiang XIANG et al., "Synthetic Peptides Reactive with Anti-Human Milk Fat Globule Membrane Monoclanal Antibodies", Cancer Research, Vol. 50, No. 1, 1 January 1990, pp. 89-96, The American Association of Immunologists, Bethesda, MD								
A-2	Vasso APOSTOLOPOULOS et al., "Anti-MUC1 Antibodies React Directly with MUC1 Peptides Presented by Class I H2 and HLA Molecules", The Journal of Immunology, Vol. 161, 1998, pp. 767-775, The American Association of Immunologists, Bethesda, MD								
A-3	Nieves DOMENECH et al., "Identification of an HLA-A11-Restricted Epitope from the Tapdem Repeat Domain of the Epithelial Tumor Antigen Mucin," The Journal of Immunology, Vol. 155, 1995, pp. 4766-4774, The American Association of Immunologists, Betheeda, Michael Park (1998).								
A-4	Vasso APOSTOLOPOULOS et al., MUC1 Peptide Epitopes Associated with Five Different H-2 Class I Molecules", European Journal Of Immunology, Vol. 27, October 1997, pp. 2579-2587, Weinheim, Verlag Chemie GmbH, Germany								
A-5	lsao NiSHIMORI et al., "N-Acetylgalactosamine Glycosylation of MUC1/andem Repeat Peptides by Pancreatic Tumor Cell Extracts". Cancer Research, Vol. 54, 15 July 1994, pp. 3738-3744, The American Association of Immunologists, Bethesda, MD								
A-6	Lior CARMON et al., "Novel Breast-Tumor-Associated MUC; Derived Peptides: Characterization in D*./-Xβ2 Microglobulin ((β2m) Null Mice Transgenic For A Chimeric HLA-A2.10") Microblobulin Single Chain", International Journal of Cancer, Vol. 85, No. 3, 1 February 2000, Wiley-Liss, New York, NY								
A-7	Peter BROSSART et al., "Identification of HLA-A2 restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies", Blood, vol. 93, No. 12, 15 June 1999, Grune & Stratton, New York								
A-8	Babita AGRAWAL et al., "The Anti-MUC1 Monoclonal Antibody VCP8 Can Be Used to Isolate and Identify Putative Major Histocompatibility Complex Class I Assopated Amine Actd", Cancer Research, Vol. 58, November 1998, pp. 5151-5156, The American Association of Immunologists, Bethesda, MD								
A-9	Janice L. KAM et al., "MUC1 Synthetic Peptide Inhibition of Intercellular Adhesion Molecule-1 and MUC1 Binding Requires Six Tandern Repeats, Cancer Research, Vol. 58, December 1998, pp. 5577-5581, The American Association of Immunologists, Bethesda, MD,								
A-10	Geoffrey A. PIETERSZ et al., "Definition of MHC-Restricted CTL Epitopes from Non-Variable Number of Tandem Repeat Sequence of MUC1", Vaccine, Vol. 18, No. 19, April 2000, pp. 2059-2071, Butterworths, Guildford, Surrey, UK								
A-11	Babita AGRAWAL et Alt., "In Vitro Induction of MUC-1 Peptide-Specific Type 1 T Lymphocyte and Cytotoxic T Lymphocyte Responses from Mealthy Multiparous Donors", Cancer Research, Vol. 58, 15 November 1998, pp. 5151-5156, The American Association of Mmunologists, Bethesda, MD								
SIA	Vasso APOSTOLOPOULOS et al., "Induction of HLA-A2-Restricted CTLs to the Mucin 1 Human Breast Cancer Antigen", The Journal of Immunology, Vol. 159, 1997, pp. 5211-5218, The American Association of Immunologists, Bethesda, MD								

Signature Considered C

Date